Petra Wilder-Smith
Petra Wilder-Smith | |
---|---|
Born | May 16, 1958 |
Residence | U.S. |
Institutions | Beckman Laser Institute; University of California, Irvine |
Alma mater | University of London, University of Bern, Aachen University |
Petra Elfrida Erna Beate Wilder-Smith (May 16, 1958- ) is a professor and director of dentistry at the Beckman Laser Institute at the University of California, Irvine, and a fellow of the Chao Family Comprehensive Cancer Center at the University of California, Irvine. She is a visiting professor at Aachen University (Germany); and a visiting lecturer at Loma Linda University. Wilder-Smith specializes in the use of light and optics in tracking and treating oral cancer. She has developed innovative[1] noninvasive laser technology used to examine and treat mouth lesions.[2]
Career
Wilder-Smith attended Guy's Hospital at the University of London (United Kingdom), receiving her degree with honors in July, 1983.[3] As of 1983, she was also licensed to perform dental surgery,[1][4] making her a Diplomate of the Royal College of Surgeons of Great Britain.[5] As of 1985, she received a doctorate from the University of Bern (Switzerland) for her work in restorative dentistry.[6]
She served as junior faculty at Guy's Hospital in the department of oral medicine and at Heidelberg University in Germany, gaining certification in the specialty of oral medicine from Heidelberg in 1986.[6] She was awarded the inaugural Research Prize for Endodontology by the European Society of Endodontology in 1987[7] for her innovative work applying Laser Doppler flowmetry techniques to oral research.[3] While at Heidelberg, she received the University's Best Clinician Award in 1988, and Best Lecturer Award and Stauffenberg Award for innovative research in 1989.[5] In 1999, Wilder-Smith was awarded a doctorate summa cum laude in biomedical optics from Aachen University.[6]
In 1991, Wilder-Smith joined the Beckman Laser Institute at the University of California, Irvine as Assistant Director of the Dental Program. She became Associate Director of the Dental Program and Adjunct Assistant Professor as of 1993, Director of Dental Program and Adjunct Assistant Professor as of 1995, Director of the Dental Program and Adjunct Associate Professor as of 1998, and Director of the Dental Program and Associate Professor in Residence as of 2003.[8]
Research
Wilder-Smith research focuses on noninvasive optical techniques such as fluorescence and optical coherence tomography and their use in the diagnosis of oral cancer. She is particularly concerned with developing technologies for the early detection of precancerous and cancerous tissues in the mouth.[9] She has collaborated with researchers at the City of Hope, UCLA, the University of Pennsylvania and elsewhere, publishing more than 100 publications in over 20 years.[10] She has received funding from the National Institutes of Health, the U.S. Department of Defense, and others.[1]
Dr. Petra Wilder-Smith is working with Dr. Zhongping Chen at the University of California, Irvine and Dr. M. A. Kuriakose at the Mazumdar-Shaw Cancer Center in Bangalore, India to develop an inexpensive portable device for detection of oral cancer,[11] which accounts for 35% of cancer deaths among Indian men.[2] The solar-powered device, slightly larger than a shoebox, uses mobile phone technology to send laser images of oral lesions to specialists for assessment.[2] Future laser devices may snap onto smartphones.[1] By reaching patients who have little access to oral care, and diagnosing cancer in its extremely early stages, the potential for early intervention and more successful treatment outcomes can be increased.[12]
The instrument sends a beam of light through oral tissue to a depth of 2 mm. This is compared to a reference beam, and an image of the tissue surface and subsurface is constructed. The information gained about the microarchitecture of the tissue is similar to that gained from histological slides in a biopsy, without invasion of the tissue and resulting pain.[13] 90% diagnostic sensitivity and 85% specificity have been reported. The system's diagnostic algorithm triages patients into three categories: no intervention required, monitor on a three- or six-month basis, and immediately refer to a specialist.[13]
Wilder-Smith serves on advisory boards of the American Society for Laser Medicine and Surgery, the Diagnostic Sciences Group of the International Association for Dental Research and the Prevent Cancer Foundation. She serves on the editorial boards of the Journal of Photomedicine and Laser Surgery and the Lasers in Surgery and Medicine journal.[5]
References
- 1 2 3 4 Vasich, Tom (August 31, 2015). "Better than biopsies". UCI News. University of California, Irvine. Retrieved 4 November 2015.
- 1 2 3 "Portable diagnostic device aimed at combating oral cancer in India". Dental Tribune International. Oct 9, 2015.
- 1 2 "Dental Notices: Congratulations" (PDF). Guy's Hospital Gazette. February 27, 1988.
- ↑ "Licence in Dental Surgery (LDS)". Royal College of Surgeons. Retrieved 4 November 2015.
- 1 2 3 "Colloquium: Petra Wilder-Smith". The University of Arizona. College of Optical Sciences. September 11, 2014.
- 1 2 3 "Biographical Sketch: Petra E. Wilder-Smith" (PDF). Beckman Laser Institute and Medical Clinic. Retrieved 4 November 2015.
- ↑ "ESE Wladimir Adlivankine Research Prize Competition". European Society of Endodontology. Retrieved 4 November 2015.
- ↑ "Wilder-Smith CV" (PDF). Beckman Laser Institute. Retrieved 4 November 2015.
- ↑ Wilder-Smith, Petra E. "A Low-Cost Simple Oral Cancer Screening Device for Low-Resource Settings". Grantome. Retrieved 4 November 2015.
- ↑ "President Elect". Diagnostic Sciences Group. Retrieved 4 November 2015.
- ↑ "Innovative Technology for Early Detection of Oral Cancer". Beckman Laser Institute and Medical Clinic. September 25, 2012.
- ↑ "Dental Research Effort Aims to Stem Oral Cancer in India". Labmedica International. 23 Sep 2015. Retrieved 4 November 2015.
- 1 2 Domino, Donna (September 24, 2015). "Can a laser detect oral cancer?". DrBicuspid.com. Retrieved 4 November 2015.